1SP

Surgery Partners Inc

Healthcare · EUR · F

1SP

Price

€11.391

+0.44%

Cap

€1.89B

Earnings

30d Trend

-8.6%

1SP
Loading chart data...
0 days · % change from startPowered by Brain47

BRAIN47 SIGNAL

0
MODERATE
Risk Level75
Quality34
Momentum26
Technical38
Fundamentals69

Raw weighted: 42×Macro 0.99 (1%)=42

RISK

75/100
90d Volatility
43.7%High
ATR %
4.1%High daily moves
Max Drawdown (1Y)
-51.8%Volatile

QUALITY

34/100
ROE (avg)
-4.5%Negative
Piotroski F-Score
5/9Average
Debt/Equity
2.18High leverage

MOMENTUM

26/100
12-1M Momentum
-35.0%Strong downtrend
6-1M Momentum
-15.0%Negative
1M Return
-6.1%Recent pullback
Relative Strength
+4.2% vs sectorIn-line

TECHNICAL

38/100
RSI (14)
44.4Neutral
Price vs SMA200
-20.5%Bearish trend
MACD
-0.12Bearish momentum
Bollinger Band
19%Near lower band
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.193Noisy/choppy

FUNDAMENTALS

69/100
EV/EBIT
13.3Cheap
P/S
2.9Fair

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months41
3-12 months24
1-5+ years42

Potential value play — but fundamentals need strengthening

BRAIN47'S ASSESSMENT

I rate Surgery Partners Inc at 42/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is fundamentals at 69/100. I classify this as a speculative position with the strongest thesis on a long-term horizon.

DETAILED ANALYSIS

Potential value play — but fundamentals need strengthening. Fundamentals (69) and Technical (38) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. I classify this as a speculative position — elevated volatility at 44% and smaller market cap define the opportunity.

speculativeScore: 42/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.